EMA Authorised: Clopidogrel TAD (clopidogrel (as hydrochloride)) — Tad Pharma GmbH

View source ↗

Summary

EMA authorised Clopidogrel TAD (clopidogrel hydrochloride) by Tad Pharma GmbH for use in peripheral vascular diseases, stroke, and myocardial infarction.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myocardial Infarction
• Peripheral Vascular Disease
• Stroke

Drugs mentioned

• Clopidogrel TAD (clopidogrel hydrochloride)

Snippet

Status: Authorised. Therapeutic area: Peripheral Vascular Diseases;Stroke;Myocardial Infarction. MAH: Tad Pharma GmbH. Decision date: 13/05/2025